Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Neoadjuvant Chemoradiotherapy in ESCC
NCT04437212Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Renji Hospital. Primary endpoint: Major Pathological Response Rate. Status: unknown.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04437212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04437212.